ArticleThe Journal of infectious diseases2025
The Effect of Preexisting Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Infection Outcomes in Exposed Household Members.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe investigated the effect of preexisting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal human coronaviruses (hCoVs) on infection outcomes in Omicron BA.1/BA.2-exposed household members from January to March 2022.
methodsData from a prospective household study in the Netherlands were used including 63 households with 195 household members exposed to a SARS-CoV-2 Omicron BA.1/BA.2 index case. The protocol included repeated nose-throat swab and saliva reverse-transcription polymerase chain reaction (RT-PCR) testing, paired serology, and self-reported daily symptom scoring by household members. Infection outcomes included the occurrence of secondary infections, symptom burden, and cycle threshold (Ct) value trajectories. We studied the effect of baseline binding antibody levels for SARS-CoV-2 and seasonal hCoVs NL63, 229E, HKU1, and OC43 spike protein, on SARS-CoV-2 infection outcomes.
resultsOne hundred thirty-two of 195 (68%) exposed household members developed a SARS-CoV-2 infection. Among exposed household members, higher levels of SARS-CoV-2 at baseline were associated with a reduced risk of secondary infection (adjusted odds ratio, 0.73 [95% confidence interval, .55-.99]). No significant differences between antibody levels and symptom burden or Ct value trajectories were observed.
conclusionsOur study suggests that prior SARS-CoV-2 antibodies provide some protection against Omicron BA.1/BA.2 infection, while effects on symptom burden or Ct value could not be demonstrated. The results highlight the relatively limited, but not negligible role of cross-protective antibodies, especially when facing immune escape variants of SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.